Sociedad Americana de Hirudoterapia

Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates

Research article published in The Journal of biological chemistry (2010)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenómica y proteómicaFarmacología salivalValnickova Z et al. · The Journal of biological chemistry, 2010

Abstract

We have previously reported that thrombin-activatable fibrinolysis inhibitor (TAFI) exhibits intrinsic proteolytic activity toward large peptides. The structural basis for this observation was clarified by the crystal structures of human and bovine TAFI. These structures evinced a significant rotation of the pro-domain away from the catalytic moiety when compared with other pro-carboxypeptidases, thus enabling access of large peptide substrates to the active site cleft. Here, we further investigated the flexible nature of the pro-domain and demonstrated that TAFI forms productive complexes with protein carboxypeptidase inhibitors from potato, leech, and tick (PCI, LCI, and TCI, respectively). We determined the crystal structure of the bovine TAFI-TCI complex, revealing that the pro-domain was completely displaced from the position observed in the TAFI structure. It protruded into the bulk solvent and was disordered, whereas TCI occupied the position previously held by the pro-domain. The authentic nature of the presently studied TAFI-inhibitor complexes was supported by the trimming of the C-terminal residues from the three inhibitors upon complex formation. This finding suggests that the inhibitors interact with the active site of TAFI in a substrate-like manner. Taken together, these data show for the first time that TAFI is able to form a bona fide complex with protein carboxypeptidase inhibitors. This underlines the unusually flexible nature of the pro-domain and implies a possible mechanism for regulation of TAFI intrinsic proteolytic activity in vivo.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsCarboxypeptidase B2CattleCrystallography, X-RayHumansProtease InhibitorsProtein BindingProtein Structure, QuaternaryProtein Structure, TertiaryStructure-Activity Relationship

Resumen

We have previously reported that thrombin-activatable fibrinolysis inhibitor (TAFI) exhibits intrinsic proteolytic activity toward large peptides.

Por qué esto importa para la hirudoterapia

This structural biology study investigated thrombin-activatable fibrinolysis inhibitor (TAFI) and demonstrated that it forms productive complexes with protein carboxypeptidase inhibitors from potato, leech, and tick (PCI, LCI, and TCI). The researchers determined the crystal structure of the bovine TAFI-TCI complex, which revealed that the pro-domain was completely displaced and disordered while the inhibitor occupied the position previously held by the pro-domain, with C-terminal residues trimmed from all three inhibitors upon complex formation. This study is relevant to the American Society of Hirudotherapy because it provides structural evidence that a leech-derived carboxypeptidase inhibitor (LCI) can form a bona fide complex with TAFI, a regulator of fibrinolysis. However, the findings are limited to in vitro crystallography, and the detailed crystal structure was determined only for the TAFI-TCI complex, not for TAFI-LCI.

Citación

Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates

Valnickova Z et al. · The Journal of biological chemistry, 2010

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.